TWI651101B - 包含阿托發司他汀（ａｔｏｒｖａｓｔａｔｉｎ）、厄貝沙坦（ｉｒｂｅｓａｒｔａｎ）及碳酸鎂之雙層複合片劑調配物 - Google Patents

包含阿托發司他汀（ａｔｏｒｖａｓｔａｔｉｎ）、厄貝沙坦（ｉｒｂｅｓａｒｔａｎ）及碳酸鎂之雙層複合片劑調配物 Download PDF

Info

Publication number
TWI651101B
TWI651101B TW102131243A TW102131243A TWI651101B TW I651101 B TWI651101 B TW I651101B TW 102131243 A TW102131243 A TW 102131243A TW 102131243 A TW102131243 A TW 102131243A TW I651101 B TWI651101 B TW I651101B
Authority
TW
Taiwan
Prior art keywords
irbesartan
pharmaceutically acceptable
layer
tablet formulation
acceptable salt
Prior art date
Application number
TW102131243A
Other languages
English (en)
Chinese (zh)
Other versions
TW201414507A (zh
Inventor
金用鎰
Yong Il Kim
趙正賢
Jung Hyun Cho
崔俊榮
Jun Young Choi
崔榮根
Young Keun Choi
朴宰賢
Jae Hyun Park
禹鍾守
Jong Soo Woo
Original Assignee
韓美藥品股份有限公司
Hanmi Pharm. Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50183917&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI651101(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 韓美藥品股份有限公司, Hanmi Pharm. Co., Ltd. filed Critical 韓美藥品股份有限公司
Publication of TW201414507A publication Critical patent/TW201414507A/zh
Application granted granted Critical
Publication of TWI651101B publication Critical patent/TWI651101B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
TW102131243A 2012-08-31 2013-08-30 包含阿托發司他汀（ａｔｏｒｖａｓｔａｔｉｎ）、厄貝沙坦（ｉｒｂｅｓａｒｔａｎ）及碳酸鎂之雙層複合片劑調配物 TWI651101B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020120096477A KR20140028971A (ko) 2012-08-31 2012-08-31 아토바스타틴, 이르베살탄 및 탄산마그네슘을 포함하는 이층정 복합제제
??10-2012-0096477 2012-08-31

Publications (2)

Publication Number Publication Date
TW201414507A TW201414507A (zh) 2014-04-16
TWI651101B true TWI651101B (zh) 2019-02-21

Family

ID=50183917

Family Applications (1)

Application Number Title Priority Date Filing Date
TW102131243A TWI651101B (zh) 2012-08-31 2013-08-30 包含阿托發司他汀（ａｔｏｒｖａｓｔａｔｉｎ）、厄貝沙坦（ｉｒｂｅｓａｒｔａｎ）及碳酸鎂之雙層複合片劑調配物

Country Status (31)

Country Link
US (1) US20150209290A1 (enExample)
EP (1) EP2890368A4 (enExample)
JP (1) JP6363079B2 (enExample)
KR (1) KR20140028971A (enExample)
CN (1) CN104602677A (enExample)
AR (1) AR092386A1 (enExample)
AU (1) AU2013309686B2 (enExample)
BR (1) BR112015004471A8 (enExample)
CA (1) CA2882735A1 (enExample)
CL (1) CL2015000402A1 (enExample)
CR (1) CR20150115A (enExample)
DO (1) DOP2015000040A (enExample)
EA (1) EA030306B1 (enExample)
EC (1) ECSP15010600A (enExample)
GT (1) GT201500043A (enExample)
IL (1) IL237424A0 (enExample)
IN (1) IN2015DN01463A (enExample)
MA (1) MA37951B2 (enExample)
MX (1) MX354800B (enExample)
MY (1) MY175897A (enExample)
NI (1) NI201500027A (enExample)
NZ (1) NZ706472A (enExample)
PE (1) PE20150935A1 (enExample)
PH (1) PH12015500394A1 (enExample)
RU (1) RU2015111546A (enExample)
SG (1) SG11201500584YA (enExample)
TW (1) TWI651101B (enExample)
UA (1) UA115995C2 (enExample)
UY (1) UY35001A (enExample)
WO (1) WO2014035188A1 (enExample)
ZA (1) ZA201502156B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6981088B2 (ja) * 2017-01-27 2021-12-15 ニプロ株式会社 経口固形製剤
AU2018301924B2 (en) * 2017-07-17 2021-07-29 Eli Lilly And Company Pharmaceutical compositions

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201200166A (en) * 2010-05-14 2012-01-01 Hanmi Holdings Co Ltd Pharmaceutical formulation in the form of bilayered tablets comprising HMG-CoA reductase inhibitor and irbesartan

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270317A (en) 1990-03-20 1993-12-14 Elf Sanofi N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present
GT199800126A (es) * 1997-08-29 2000-01-29 Terapia de combinacion.
US20030114497A1 (en) 2001-07-31 2003-06-19 Laman Alani Pharmaceutical compositions of amlodipine and atorvastatin
PE20080183A1 (es) * 2006-04-06 2008-03-10 Schering Corp Terapias de combinacion de tra
KR101230731B1 (ko) * 2008-04-29 2013-02-07 한올바이오파마주식회사 약제학적 제제
WO2011121824A1 (ja) * 2010-03-29 2011-10-06 アステラス製薬株式会社 口腔内崩壊錠

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201200166A (en) * 2010-05-14 2012-01-01 Hanmi Holdings Co Ltd Pharmaceutical formulation in the form of bilayered tablets comprising HMG-CoA reductase inhibitor and irbesartan

Also Published As

Publication number Publication date
GT201500043A (es) 2017-08-24
US20150209290A1 (en) 2015-07-30
JP2015530384A (ja) 2015-10-15
MX2015002526A (es) 2015-06-23
ECSP15010600A (es) 2015-12-31
EP2890368A4 (en) 2016-03-02
KR20140028971A (ko) 2014-03-10
CL2015000402A1 (es) 2015-06-05
PE20150935A1 (es) 2015-06-20
NZ706472A (en) 2018-02-23
TW201414507A (zh) 2014-04-16
UA115995C2 (uk) 2018-01-25
BR112015004471A8 (pt) 2019-08-27
BR112015004471A2 (pt) 2017-07-04
AU2013309686A1 (en) 2015-02-26
IN2015DN01463A (enExample) 2015-07-03
UY35001A (es) 2014-03-31
MA37951B2 (fr) 2019-12-31
CA2882735A1 (en) 2014-03-06
EP2890368A1 (en) 2015-07-08
DOP2015000040A (es) 2015-04-15
ZA201502156B (en) 2016-07-27
AU2013309686B2 (en) 2017-09-07
JP6363079B2 (ja) 2018-07-25
RU2015111546A (ru) 2016-10-20
WO2014035188A1 (en) 2014-03-06
CN104602677A (zh) 2015-05-06
SG11201500584YA (en) 2015-02-27
AR092386A1 (es) 2015-04-22
NI201500027A (es) 2017-01-04
MY175897A (en) 2020-07-14
CR20150115A (es) 2015-04-16
MA37951A1 (fr) 2018-06-29
PH12015500394A1 (en) 2015-04-27
EA030306B1 (ru) 2018-07-31
EA201590469A1 (ru) 2015-06-30
IL237424A0 (en) 2015-04-30
MX354800B (es) 2018-03-22

Similar Documents

Publication Publication Date Title
CN102085201B (zh) 阿替洛尔和氨氯地平的双层片剂
JP5969466B2 (ja) ＨＭＧ−ＣｏＡ還元酵素阻害剤及びイルベサルタンを含む二層錠の薬学的剤型
JP6068765B2 (ja) 薬学的複合製剤
TWI816080B (zh) 包括阿托伐他汀以及怡妥錠的雙層片劑及其製造方法
TW202416994A (zh) 固定劑量醫藥組合物及其用途
JP7094944B2 (ja) ロスバスタチン及びエゼチミブを含む医薬組成物並びにその調製方法
WO2017186593A1 (en) Tablets comprising mirabegron and solifenacin
CA2927720A1 (en) Composite formulation comprising tadalafil and amlodipine
CN101052380A (zh) 双层片剂
US20120141586A1 (en) Thrombin receptor antagonist and clopidogrel fixed dose tablet
US20120107397A1 (en) Pharmaceutical compositions of valsartan
TW201944992A (zh) 包含依折麥布(ezetimibe)以及瑞舒伐他汀(rosuvastatin)的藥學組合製品
CN101804029A (zh) 阿托伐他汀脂质体、其制备方法及含有它的药物组合物
JPWO2008001734A1 (ja) 圧縮製剤
KR101171375B1 (ko) 난용성 약물을 함유하는 경구 제형
KR102314015B1 (ko) 이층정제 및 이의 제조 방법
JP6363079B2 (ja) アトルバスタチン、イルベサルタンおよび炭酸マグネシウムを含有する二層複合錠製剤
CN104739833A (zh) 含替米沙坦和瑞舒伐他汀钙的复方双层片剂及其制备方法
JP5241511B2 (ja) 溶出性の改善された医薬組成物
TW200835525A (en) Method for improvement of elution
RU2677649C2 (ru) Фармацевтические композиции монтелукаста и левоцетиризина
TWI720115B (zh) 一種含有喹啉衍生物或其鹽的醫藥組成物的製備方法
KR20180060705A (ko) 에제티미브 및 로수바스타틴을 포함하는 경구용 복합정제
SG11202106025WA (en) Tablet and method of preparing same
RU2479310C2 (ru) Фармацевтическая композиция для лечения артериальной гипертензии и застойной сердечной недостаточности и способ ее получения

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees